Tilray Medical Germany Launches ARX Cannabis Brand from EU-GMP Aphria RX Facility

Domestic cultivation under EU-GMP conditions is now the baseline expectation for medical cannabis entering the German market, and Tilray Medical Germany's launch of ARX™ from its Aphria RX facility in Neumünster signals how seriously established operators are treating that standard. The brand, more than two years in development, represents the company's first premium cannabis line cultivated entirely in-country.

For QA directors and plant heads, the operational architecture behind ARX carries more weight than the brand name. Aphria RX runs individual, climate-controlled grow rooms that allow cultivar-specific environmental parameters, with continuous monitoring and real-time process adjustments built into the cultivation workflow. Tilray states the fully integrated, in-house model eliminates irradiation by reducing external handling, a claim that will draw scrutiny from pharmacists and regulators assessing product integrity documentation.

Strain genetics are drawn exclusively from Broken Coast's library, a Canadian licensed producer active since 2014 with documented expertise in phenotyping and strain selection. Transferring that genetic programme into a 21 CFR Part 211-adjacent EU-GMP framework requires rigorous process validation to demonstrate that cultivar performance translates consistently across geographies and facility configurations, an area regulators will expect to see substantiated in batch records and process capability data.

Distribution runs through CC Pharma and 14U Pharma, Tilray's established German pharmacy channels, giving ARX immediate national reach. Rajnish Ohri, President International at Tilray Brands, cited supply reliability and long-term patient access as core commitments, framing domestic production as a structural hedge against the import dependency that has historically created availability gaps in the German medical cannabis supply chain.

ARX makes its public debut at Mary Jane Berlin 2026, Hall 20, Stand B21, where healthcare professionals can review product documentation directly with Tilray Medical representatives.

Whether Aphria RX's batch release data and process validation packages can support the consistency claims at commercial scale will be the measurable checkpoint regulators and dispensing pharmacists will apply as ARX moves from launch into routine supply.

Source: Tilray Brands, Inc. via GlobeNewswire, 10 June 2026.